Accord Healthcare has announced the launch of a UK generic rival to Revlimid (lenalidomide) capsules, leading off a year that is also expected to see competition to the blockbuster Bristol Myers Squibb Company brand elsewhere in Europe as well as in the US.
The launch had been expected after Accord in 2018 settled UK litigation with Celgene, now part of BMS, in which...